The ethics of CYP2D6 testing for patients considering tamoxifen

doi:10.1186/bcr1663

Breast Cancer Research

Volume 9
Issue 2

Viewing options:

Abstract
Full text
PDF (39KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Hartman AR
Helft P

on PubMed

Hartman AR
Helft P
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Commentary

The ethics of CYP2D6 testing for patients considering tamoxifen

Anne-Renee Hartman¹ and Paul Helft²

¹1155 Merrill Street, #102, Menlo Park, CA 94025, USA

²Indiana University, Division of Hematology/Oncology, 535 Barnhill Drive, RT473, Indianapolis, IN 46202, USA

author email corresponding author email

Breast Cancer Research 2007, 9:103doi:10.1186/bcr1663


Published:	13 April 2007

Abstract

The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.